Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...5556575859606162636465...123124»
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. (Pubmed Central) -  Jun 22, 2022   
    Moreover, a total of six key differential genes, namely, ALB, CCND1, ESR1, AR, CCNA2, and AURKA, were identified as most significant targets associated with lenvatinib treating HCC and further verified by molecular docking, which demonstrated that lenvatinib had a strong binding efficiency with these six key gene-encoded proteins. Taken together, this study systematically provided new insights for researchers to determine the intervention mechanisms of lenvatinib in HCC therapy.
  • ||||||||||  MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) (clinicaltrials.gov) -  Jun 21, 2022   
    P1,  N=442, Recruiting, 
    Our study showed that a combination of lenvatinib with the PD-1 inhibitor could be an effective treatment for advanced intrahepatic cholangiocarcinoma after the chemorefractory effect. Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Jemperli (dostarlimab) / GSK
    Journal:  Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey. (Pubmed Central) -  Jun 14, 2022   
    As for MSS patients, 77.8% of clinicians would choose lenvatinib plus pembrolizumab for them in second line once approved. Despite the selected sample of respondents from Italian MITO centres showing good knowledge of diagnostic and therapeutic innovations in EC, these are not fully implemented in everyday clinics, except for MSI status assessment.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) -  Jun 13, 2022   
    P1,  N=20, Not yet recruiting, 
    Despite the selected sample of respondents from Italian MITO centres showing good knowledge of diagnostic and therapeutic innovations in EC, these are not fully implemented in everyday clinics, except for MSI status assessment. Trial completion date: Nov 2023 --> Apr 2024 | Initiation date: Jan 2022 --> Aug 2022 | Trial primary completion date: Nov 2023 --> Apr 2024
  • ||||||||||  Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen, Tecentriq (atezolizumab) / Roche
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Emerging Therapies for Hepatocellular Carcinoma (HCC). (Pubmed Central) -  Jun 11, 2022   
    In this context, identification of appropriate gene targets and specific gene delivery approaches create the potential of gene- and immune-based therapies for the safe and effective treatment of HCC. This review elaborates on the current status of HCC treatment by focusing on potential gene targets and advanced techniques, such as oncolytic viral vectors, nanoparticles, chimeric antigen receptor (CAR)-T cells, immunotherapy, and clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9), and describes future prospects in HCC treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca, Tecentriq (atezolizumab) / Roche
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. (Pubmed Central) -  Jun 8, 2022   
    Breast cancer has traditionally been viewed as immunogenically 'cold,' but two immune checkpoint inhibitors have been approved in combination with chemotherapy for PD-L1 positive advanced triple-negative breast cancer (TNBC), and pembrolizumab was also recently approved for early stage TNBC...A number of novel combination strategies are under investigation to enhance response and overcome resistance to immunotherapy, with promising preliminary data from checkpoint inhibitors targeting TIGIT, combinations with small molecule inhibitors such as lenvatinib, and injectable agents directly influencing the immune microenvironment. As immunotherapy enters into the curative setting, biomarkers predictive of immunotherapy benefit are needed, as PD-L1 status has not been a helpful discriminator in completed trials in early-stage breast cancer.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, IO biomarker:  Novel Therapeutics for Advanced Differentiated Thyroid Cancer. (Pubmed Central) -  Jun 8, 2022   
    Next-generation sequencing allows for the use of tumor-targeted therapeutics, such as MEK1/2, BRAF, RET, and NTRK inhibitors. Immunotherapy is also under investigation as a therapeutic option for this disease.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment change:  LITESPARK-016: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (clinicaltrials.gov) -  Jun 8, 2022   
    P2,  N=730, Recruiting, 
    The present study showed that u-HCC patients who received Atez/Bev as a first-line treatment may have a better prognosis than those who received lenvatinib. N=400 --> 730
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  PECATI: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (clinicaltrials.gov) -  Jun 7, 2022   
    P2,  N=43, Recruiting, 
    Comparison between patients in Study 202 and REFLECT demonstrates efficacy was maintained with improved safety in patients with lower bodyweights who received lenvatinib 8 mg/day in REFLECT versus patients who received lenvatinib 12 mg/day in Study 202. Trial completion date: Mar 2023 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  Review, Journal:  First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. (Pubmed Central) -  Jun 4, 2022   
    These trials include CheckMate214 (ipilimumab plus nivolumab), KEYNOTE 426 (pembrolizumab plus axitinib), JAVELIN Renal 101 (avelumab plus axitinib), CheckMate 9ER (nivolumab plus cabozantinib), and the CLEAR study (lenvatinib and pembrolizumab)...The broadening spectrum of treatment options for patients with mccRCC with multiple first-line options currently available also means that treating physicians will need to consider each option carefully, balance clinical factors, financial considerations, and weigh toxicity profiles of each drug before deciding the optimal treatment regimen for each individual patient. We describe each frontline treatment option in detail through this review to aid the decision-making process.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal, Combination therapy:  Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis. (Pubmed Central) -  Jun 4, 2022   
    This result was also reproduced in the multivariate analysis adjusted for α-fetoprotein, another significant prognostic factor in this study, and the well-known prognostic factors, namely the presence of main portal vein tumor thrombosis and albumin-bilirubin grade. The combination of lenvatinib and LRT is relatively safe and effective in increasing the intrahepatic tumor response and improving PFS and IHPFS in patients with HCC and macroscopic tumor thrombosis.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial suspension:  Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors (clinicaltrials.gov) -  Jun 3, 2022   
    P2,  N=35, Suspended, 
    The combination of lenvatinib and LRT is relatively safe and effective in increasing the intrahepatic tumor response and improving PFS and IHPFS in patients with HCC and macroscopic tumor thrombosis. Recruiting --> Suspended